SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HuMAB companies
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who wrote (832)11/6/2006 3:45:03 AM
From: nigel bates   of 1022
 
...and from Friday's Peptech annual report -

...Domantis currently has collaboration and license agreements with Peptech Limited, Abbott Laboratories, ImClone Systems, Argenta Discovery and Tanox and a multi-target discovery collaboration with Bristol-Myers Squibb Company (NYSE: BMY). Further alliances to discover and develop multiple therapeutic human domain antibody products are anticipated.
Domantis has more than a dozen proprietary domain antibody therapeutic programs, primarily in the fields of inflammation and oncology and is taking several domain antibody product leads into clinical testing - both on its own and through strategic alliances and co-development arrangements. Clinical validation of dAbs in humans will commence for select dAbs in 2007 (including Peptech’s anti-TNF product, PN0621, which is likely to be the first dAb to enter the clinic – planned for the second quarter of 2007).
Domantis is in the process of strengthening its Board and management team to position the company for a NASDAQ listing in the coming years and in June announced the appointment in the USA of a highly credentialed Chief Financial Officer. Greg Perry comes to Domantis with over 20 years of experience in senior financial management for major American companies including PerkinElmer, Honeywell and General Electric (GE) and was most recently Senior Vice President and Chief Financial Officer at Transkaryotic Therapies (TKT). ...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News